Johnson & Johnson 10-K Summary: Fiscal Year Ended January 2, 2005
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended January 2, 2005. Johnson & Johnson is a global healthcare company employing approximately 109,900 people across over 200 subsidiaries in virtually all countries. The company operates through three primary segments: Consumer (baby care, skin care, OTC pharmaceuticals), Pharmaceutical (prescription drugs), and Medical Devices and Diagnostics. The company is organized on a decentralized management principle, with subsidiaries largely managed by local citizens.
Key Financial Metrics
The provided text incorporates detailed financial statements by reference to the Annual Report to Shareholders (Exhibit 13) and does not explicitly list total revenue, net income, or cash flow figures in the narrative sections. However, the following specific financial data points are disclosed:
- Research and Development Costs: $5,203 million for fiscal year 2004 (compared to $4,684 million in 2003 and $3,957 million in 2002). These costs are charged directly to income.
- Valuation and Qualifying Accounts (2004):
- Accrued rebates, returns, and promotions: $2,785 million (ending balance).
- Reserve for doubtful accounts: $206 million (ending balance).
- Reserve for cash discounts: $62 million (ending balance).
- Share Repurchases (Fiscal 2004): The company purchased shares throughout the year as part of a systematic plan. The average price per share ranged from $52.03 to $62.69 during the reported months.
- Market Capitalization: Approximately $161 billion (as of the last business day of the most recently completed second fiscal quarter).
- Outstanding Shares: 2,973,666,464 shares of Common Stock as of March 1, 2005.
Note: Specific values for total revenue, profit margins, debt levels, and liquidity ratios are not present in the provided text and are incorporated by reference to the Annual Report.
Material Changes and Operational Highlights
- Patent Expirations and Generic Competition:
- DURAGESIC (Fentanyl): Pediatric exclusivity expired in the U.S. in January 2005, and the first generic version has launched. Foreign patent protection expires during 2005. The company expects sales to decline in 2005 compared to 2004.
- EPREX (PROCRIT outside U.S.): Patents expired in certain international markets during 2004. Generic competition is expected to be limited in the near term due to the lack of biologically equivalent compounds.
- Revenue Impact: DURAGESIC and EPREX accounted for over 7% of worldwide sales in 2004. PROCRIT and RISPERDAL each accounted for over 5% of total revenues in 2004.
- Seasonality: Worldwide sales do not reflect significant seasonality, though spending is heavier in the fourth quarter due to advertising and research grants.
- Legal Proceedings: The company is involved in Superfund proceedings regarding environmental remediation costs. Management does not believe these will have a material adverse effect on operations or financial position.
Outlook, Risks, and Management Commentary
- Regulatory Environment: The company faces increasing stringency in government regulation, particularly regarding product safety, efficacy, and pricing. The impact of the Medicare Prescription Drug, Improvement and Modernization Act (enacted late 2003) remains uncertain.
- Industry Risks: Developments involving COX-2 inhibitor medicines (e.g., Vioxx, Celebrex) are likely to have implications throughout the healthcare industry, despite J&J not selling COX-2 inhibitors.
- Internal Controls: Management concluded that internal control over financial reporting was effective as of January 2, 2005, based on COSO criteria. This assessment was audited by PricewaterhouseCoopers LLP.
- Capital Resources: Specific liquidity and capital resource details are incorporated by reference to the Annual Report. The company maintains a systematic share repurchase plan.
Investor Verification Checklist
- Verify the specific impact of DURAGESIC and EPREX patent expirations on 2005 revenue projections in the full Annual Report.
- Review the "Summary of Operations and Statistical Data" (Exhibit 13, page 65) for total revenue, net earnings, and cash flow figures not detailed in this text.
- Examine the "Legal Proceedings" note (Exhibit 13, pages 56-61) for details on specific litigation risks beyond the general Superfund disclosures.
- Confirm the status of the Medicare Prescription Drug Act's impact on pricing strategies in the full MD&A section.
- Review the "Liquidity and Capital Resources" section (Exhibit 13, pages 34-35) for detailed debt and cash position data.